JHL Becomes Eden And Announces Denosumab Progress
Offers Phase I And III Updates On Biosimilar Rival To Amgen’s Prolia
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
You may also be interested in...
Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.
Eden Biologics has sold its CDMO business to Bora Pharmaceuticals’ recently-established biologics CDMO platform Bora Biologics. The firm appears keen to maintain a working relationship with its former unit following the sale.
Two former JHL Biotech executives have been handed prison sentences after pleading guilty to a charge of conspiracy to commit theft of trade secrets and wire fraud, in relation to the Taiwanese firm’s development of multiple biosimilars.